The Health Care Select Sector SPDR® Fund Newsroom

Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry

Benzinga18minutes ago

Unpacking the Latest Options Trading Trends in Eli Lilly

Benzinga10:16 ET

BioNTech Raised to Buy at Jefferies on New Cancer Drug

Seeking Alpha10:12 ET

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Ahead of US FOMC Policy Meeting

MT Newswires08:28 ET

TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades'

Benzinga07:55 ET

Senseonics Eversense 365 Glucose Monitor Cleared in the U.S.

Seeking Alpha07:52 ET

Sector-wise Weekly ETF Flows - Money Pours Out of Financials and Into Consumer Staples

Seeking Alpha03:36 ET

BeyondSpring Plinabulin, Merck Keytruda Combo Shows Promise in NSCLC

Seeking Alpha17:14 ET

What the Options Market Tells Us About UnitedHealth Group

Benzinga15:15 ET

A Closer Look at 8 Analyst Recommendations For Merck & Co

Benzinga15:00 ET

CG Oncology Surges 7%; Seen Benefitting From J&J Bladder Cancer Asset Data

Seeking Alpha12:46 ET

Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $155 Price Target

Benzinga12:17 ET · Ratings

Merck & Co Analyst Ratings

Benzinga12:15 ET · Ratings

Eli Lilly Analyst Ratings

Benzinga12:03 ET · Ratings

Moderna Was Most Shorted S&P 500 Healthcare Stock in August for Second Consecutive Month

Seeking AlphaSep 16 10:49 ET

NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges

BenzingaSep 16 09:28 ET

Johnson & Johnson Analyst Ratings

BenzingaSep 16 08:18 ET · Ratings

Immutep's Efti In Combination With MSD's KEYTRUDA Leads To Efficacy With Favourable Safety In First Line Head And Neck Cancer

BenzingaSep 16 08:15 ET

Thermo Fisher Scientific Analyst Ratings

BenzingaSep 16 08:14 ET · Ratings

Reported Saturday, Johnson & Johnson Shares New Data on RYBREVANT in Metastatic Colorectal Cancer at ESMO Congress

BenzingaSep 16 03:01 ET